{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:01Z","timestamp":1761929461679},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00277-010-0907-3","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T04:48:12Z","timestamp":1266382092000},"page":"531-533","source":"Crossref","is-referenced-by-count":3,"title":["Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?"],"prefix":"10.1007","volume":"89","author":[{"given":"A. M.","family":"Carella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"key":"907_CR1","doi-asserted-by":"crossref","unstructured":"Deininger MW (2008) Chronic myeloid leukemia. An historical perspective. Hematology 418\u2013426","DOI":"10.1182\/asheducation-2008.1.418"},{"issue":"1","key":"907_CR2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","volume":"2009","author":"D Bixby","year":"2009","unstructured":"Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology 2009(1):461\u2013476","journal-title":"Hematology"},{"issue":"1","key":"907_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/asheducation-2009.1.453","volume":"2009","author":"JM Goldman","year":"2009","unstructured":"Goldman JM (2009) Initial treatment for CML. Hematology 2009(1):453\u2013460","journal-title":"Hematology"},{"key":"907_CR4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I et al (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL positive acute lymphoblastic leucemia: a phase II study by the Japan Adult Leucemia Study Group. J Clin Oncol 24:460\u2013466","journal-title":"J Clin Oncol"},{"key":"907_CR5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lheritier V et al (2006) Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20:1526\u20131532","journal-title":"Leukemia"},{"key":"907_CR6","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G et al (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematogiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676\u20133678","journal-title":"Blood"},{"key":"907_CR7","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H et al (2007) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). Cancer 109:2068\u20132076","journal-title":"Cancer"},{"key":"907_CR8","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"907_CR9","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"As Corbin","year":"2003","unstructured":"Corbin As, La Rosee P, Stroffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611\u20134614","journal-title":"Blood"},{"key":"907_CR10","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res."},{"key":"907_CR11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029","journal-title":"Lancet Oncol"},{"key":"907_CR12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL). Blood 110:727\u2013734","journal-title":"Blood"},{"key":"907_CR13","doi-asserted-by":"crossref","unstructured":"Carella AM (2009) Finding of kinase domain mutations of BCR-ABL at diagnosis before Imatinib-based therapy give rise to progression in high Sokal risk chronic phase chronic myeloid leukemia (CP-CML). Leukemia & Lymphoma; In press","DOI":"10.3109\/10428190903503446"},{"key":"907_CR14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"N Shah","year":"2002","unstructured":"Shah N, Nicoli J, Nagar B et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blastic chronic myeloid leukaemia. Cancer Cell 2:117\u2013223","journal-title":"Cancer Cell"},{"key":"907_CR15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571\/Imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831\u2013843","journal-title":"Cell"},{"key":"907_CR16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, Muller MC, Lahaye T et al (2002) Molecular and chromosomal mechanims of resistance to imatinib (STI571) therapy. Leukemia 16:2190\u20132196","journal-title":"Leukemia"},{"key":"907_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"907_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"907_CR19","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+neoplastic cells. Cancer Res 66:11314\u201311322","journal-title":"Cancer Res"},{"key":"907_CR20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade De","year":"2008","unstructured":"De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358\u20133363","journal-title":"J Clin Oncol"},{"key":"907_CR21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","volume":"4","author":"M Carmena","year":"2003","unstructured":"Carmena M, Earnshaw WC (2003) The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 4:842\u2013854","journal-title":"Nat Rev Mol Cell Biol."},{"key":"907_CR22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ceb.2003.10.013","volume":"15","author":"PD Andrews","year":"2003","unstructured":"Andrews PD, Knatko E, Moore WJ, Swedlow JR (2003) Mitotic mechanics: the Auroras come into view. Curr Opin Cell Biol 15:672\u2013683","journal-title":"Curr Opin Cell Biol."},{"key":"907_CR23","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/sj.onc.1208752","volume":"24","author":"PD Andrews","year":"2005","unstructured":"Andrews PD (2005) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005\u20135015","journal-title":"Oncogene"},{"key":"907_CR24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc1502","volume":"4","author":"N Keen","year":"2004","unstructured":"Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927\u2013936","journal-title":"Nat Rev Cancer"},{"key":"907_CR25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","volume":"66","author":"MA Young","year":"2006","unstructured":"Young MA, Shah NP, Chao LH et al (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66:1007\u20131014","journal-title":"Cancer Res"},{"key":"907_CR26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Gilles","year":"2007","unstructured":"Gilles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500\u2013502","journal-title":"Blood"},{"key":"907_CR27","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","volume":"8","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E et al (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 8:4355\u20134364","journal-title":"Blood"},{"key":"907_CR28","unstructured":"Cortes-Franco J, Raghunadharao D, Parikh P et al (2009) Safety and efficacy of subcutaneous-administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) patients who are resistant or intollerant to two or more tyrosine kinase inhibitors\u2014results of a multicenter phase 2\/3 study. Abs 861, ASH Annual Meeting Abstracts Vol. 114, 20: 354"},{"key":"907_CR29","unstructured":"Seitz AK, von Bubnoff N, Sarno SM et al (2009) Activity of serono-AS703569, a dual inhibitor of BCR-ABL and aurora kinases in BCR-ABL transformed cells, is dependent on aurora B inhibition and is not affected by the presence of the highly Imatinib resistant BCR-ABL mutation T315I. Abs 3247, ASH Annual Meeting Abstracts Vol. 114, 20:1258"},{"key":"907_CR30","unstructured":"Minami Y, Minami M, Kuwatsuka Y et al (2009) Treatment with mTOR inhibitor, Everolimus (RAD001) overcomes resistance to imatinib in Ph-leukemia quiescent or T315I-mutated cells. Abs 3277, ASH Annual Meeting Abstracts Vol. 114, 20:1269"},{"key":"907_CR31","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"N Shah","year":"2007","unstructured":"Shah N, Skaggs BJ, Branford S et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562\u20132569","journal-title":"J Clin Invest"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0907-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-0907-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0907-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:50:11Z","timestamp":1559022611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-0907-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,18]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-0907-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,18]]}}}